Skip to content
DraconiticResearch
Search Sources API
203,234 studies31 sourcesUpdated 59 min ago
Peer-reviewedCC BYCancer chemotherapy and pharmacology

Successful treatment with BrECADD in a patient with Dubin-Johnson syndrome and classic Hodgkin lymphoma: a case report.

  • Hishan Tharmaseelan1
  • Christian Peter Jaworek2
  • Peter Borchmann2
  • Conrad-Amadeus Voltin3,4
  • Martin Galler5
  • Gareth J Veal5
  • Louisa Lepkes6
  • Björn Reusch6
  • Clara Velmans6
  • Christian Netzer6
  • Wenyu Yang7
  • Uwe Fuhr7
1 more authors
  • Shelby Barnett5
7 affiliations
  1. 1Faculty of Medicine and University Hospital of Cologne, Department I of Internal Medicine, and Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD), German Hodgkin Study Group (GHSG), University of Cologne, Kerpener Str 62, 50937, Cologne, Germany. [email protected].
  2. 2Faculty of Medicine and University Hospital of Cologne, Department I of Internal Medicine, and Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD), German Hodgkin Study Group (GHSG), University of Cologne, Kerpener Str 62, 50937, Cologne, Germany.
  3. 3Department of Nuclear Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
  4. 4Molecular Imaging and Therapy Service, Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  5. 5Newcastle University Centre for Cancer, Newcastle University, Newcastle upon Tyne, UK.
  6. 6Institute of Human Genetics, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
  7. 7Clinical Pharmacology, Department I of Pharmacology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
Read full textPDFDOICite

Abstract

Dubin-Johnson syndrome (DJS) results from ABCC2/MRP2 mutations causing impaired biliary transport. MRP2 also mediates hepatic elimination of chemotherapeutic agents, yet no data exist on anthracycline-based chemotherapy in adult DJS patients. We report a 26-year-old male with advanced-stage classic Hodgkin lymphoma and DJS harboring a novel homozygous ABCC2 variant (c.2291G>A, p.Gly764Asp). After a pembrolizumab prephase, full-dose BrECADD was administered, and samples were taken for therapeutic drug monitoring (TDM), which demonstrated normal etoposide and doxorubicin pharmacokinetics. Complete metabolic remission was achieved without significant toxicity. This case demonstrates that TDM-guided, full-dose anthracycline-based chemotherapy is feasible in DJS.

Related

  1. Successful Treatment with Epcoritamab for Refractory Diffuse Large B-cell Lymphoma in a Dialysis-dependent Patient
    Yuya Sasaki, Keisuke Tanaka, Hisako Nakamaki +4
    Internal MedicinePeer-reviewedCC BY-NC-NDFull textGeneral medicineJ-STAGE
  2. Successful salvage therapy with glofitamab followed by selinexor maintenance in an elderly patient with primary refractory diffuse large b-cell lymphoma harboring TP53 and CD58 mutations: a case report and literature review
    Yurong Zhang, Huan Liu, Liangliang Li +5
    Frontiers in OncologyPeer-reviewedCC BY 4.0Full textOncologyCrossref
  3. Successful treatment of lamotrigine-induced Stevens-Johnson syndrome with upadacitinib.
    Amishi Taneja, Jacob Kingsley, Severine Z Cao +2
    JAAD case reportsPeer-reviewedCC BYFull textPharmacology & toxicologyEurope PMC
  4. Successful Treatment of an Atypical Mycobacterial Exit Site Infection in a Patient on Peritoneal Dialysis: A Case Report
    Michael Shye, Anita D Sircar, Ramya Malchira +2
    CureusPeer-reviewedCC BYFull textGeneral medicineEurope PMC
  5. Successful Implementation of Peripheral Venoarterial ECMO in a Patient With Eisenmenger Syndrome as a Bridge to Lung Transplant: A Case Report
    Ashie Kapoor, Nicole Shalit, June Tong +1
    Journal of Investigative Medicine High Impact Case ReportsPeer-reviewedCC BY-NC 4.0Full textCardiovascular medicinePMC

Cite

BibTeXRIS
BibTeX
@article{tharmaseelan2026successful,
  title = {{Successful treatment with BrECADD in a patient with Dubin-Johnson syndrome and classic Hodgkin lymphoma: a case report.}},
  author = {Hishan Tharmaseelan and Christian Peter Jaworek and Peter Borchmann and Conrad-Amadeus Voltin and Martin Galler and Gareth J Veal and Louisa Lepkes and Björn Reusch and Clara Velmans and Christian Netzer and Wenyu Yang and Uwe Fuhr and Shelby Barnett},
  journal = {Cancer chemotherapy and pharmacology},
  year = {2026},
  month = oct,
  doi = {10.1007/s00280-026-04975-w},
  url = {https://europepmc.org/article/MED/42909633},
  note = {CC BY},
}
RIS
TY  - JOUR
TI  - Successful treatment with BrECADD in a patient with Dubin-Johnson syndrome and classic Hodgkin lymphoma: a case report.
AU  - Hishan Tharmaseelan
AU  - Christian Peter Jaworek
AU  - Peter Borchmann
AU  - Conrad-Amadeus Voltin
AU  - Martin Galler
AU  - Gareth J Veal
AU  - Louisa Lepkes
AU  - Björn Reusch
AU  - Clara Velmans
AU  - Christian Netzer
AU  - Wenyu Yang
AU  - Uwe Fuhr
AU  - Shelby Barnett
PY  - 2026
DA  - 2026/10/23
JO  - Cancer chemotherapy and pharmacology
DO  - 10.1007/s00280-026-04975-w
UR  - https://europepmc.org/article/MED/42909633
AB  - Dubin-Johnson syndrome (DJS) results from ABCC2/MRP2 mutations causing impaired biliary transport. MRP2 also mediates hepatic elimination of chemotherapeutic agents, yet no data exist on anthracycline-based chemotherapy in adult DJS patients. We report a 26-year-old male with advanced-stage classic Hodgkin lymphoma and DJS harboring a novel homozygous ABCC2 variant (c.2291G>A, p.Gly764Asp). After a pembrolizumab prephase, full-dose BrECADD was administered, and samples were taken for therapeutic drug monitoring (TDM), which demonstrated normal etoposide and doxorubicin pharmacokinetics. Complete metabolic remission was achieved without significant toxicity. This case demonstrates that TDM-guided, full-dose anthracycline-based chemotherapy is feasible in DJS.
SN  - 0344-5704
SN  - 1432-0843
ER  -